New Japanese Global Clinical Trial Requirements Could Help MNCs – BIO-Asia Panel
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Efforts by Japanese regulators to better equip local pharmaceutical companies for the global marketplace could also pay dividends for Western multinationals looking to secure marketing authorization in Japan, according to a recent panel discussion during BIO-Asia in Tokyo
You may also be interested in...
Forget China And India, Clinical Trial Opportunities In Malaysia and South Korea
The opportunities for clinical trials in China and India are well known to the pharmaceutical industry at this point, but Edward Ian, senior director of clinical operations for PRA International-Asia Pacific, wants company leaders to take notice and advantage of the potential in other countries in Asia Pacific
Forget China And India, Clinical Trial Opportunities In Malaysia and South Korea
The opportunities for clinical trials in China and India are well known to the pharmaceutical industry at this point, but Edward Ian, senior director of clinical operations for PRA International-Asia Pacific, wants company leaders to take notice and advantage of the potential in other countries in Asia Pacific
Japanese Pharma Looking Beyond Japan For Clinical Trials
TOKYO - Japanese pharmaceutical manufacturers are diversifying their Phase III clinical trials away from Japan to establish development footholds into fast-developing East Asia and other regions where costs are low and trial patients can be secured with ease